Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-α treatment response in rheumatoid arthritis

Rheumatology International

Volumn 30, Issue 4, 2010, Pages 451-454

  Dejaco, Christian ^a   Duftner, Christina ^a   Klotz, Werner ^b   Schirmer, Michael ^a,b   Herold, Manfred ^b  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Autoantibodies; Cyclic citrullinated peptide; Rheumatoid arthritis; Tumour necrosis factor a inhibitors

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE 3 ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; BLOOD; DISEASE COURSE; DRUG ANTAGONISM; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949907279     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-0978-4     Document Type: Article

References (11)

1. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL (2007) The eYcacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66:1473-1478. doi:10.1136/ard.2007.072447 (Pubitemid 350032655)
2. Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C (2007) Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 1109:287-295. doi:10.1196/annals.1398.034 (Pubitemid 47511371)
3. Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL (2005) Adalimumab clinical eYcacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titre reduction: a one-year prospective study. Arthritis Res Ther 8:R3. doi:10.1186/ar1851
4. Lutteri L, Malaise M, Chapelle JP (2007) Comparison of secondand third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386:76-81. doi:10.1016/j.cca. 2007.08.002 (Pubitemid 47417966)
5. Luis Caro-Oleas J, Fernández-Suárez A, Reneses Cesteros S, Porrino C, Núñez-Roldán A, Wichmann Schlipf I (2007) Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med 45:1396-1401. doi:10.1515/CCLM.2007.294 (Pubitemid 47557085)
6. Dos Anjos LM, Pereira IA, d'Orsi E, Seaman AP, Burlingame RW, Morato EF (2009) A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153-158. doi:10.1007/s10067-008-0999-5
7. Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M (2008) Antibodies against mutated citrullinated vimentin fail to predict anti-TNF alpha treatment response in rheumatoid arthritis. Scand J Rheumatol 38:66-67
8. van Gestel AM, Prevoo ML, Van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism criteria. Arthritis Rheum 39:34-40. doi:10.1002/art.1780390105 (Pubitemid 26036375)
9. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5:59-63. doi:10.1038/ncb898 (Pubitemid 36054330)
10. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P (2005) Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 1051:559-569. doi:10.1196/annals.1361.100 (Pubitemid 41362783)
11. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66:302-307. doi:10.1136/ard.2006.060608 (Pubitemid 46579628)